Published in Bioorg Med Chem Lett on March 30, 2010
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature (2012) 2.21
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci (2014) 1.74
Light-controlled modulation of gene expression by chemical optoepigenetic probes. Nat Chem Biol (2016) 1.49
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One (2015) 1.40
Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell (2013) 1.37
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr Opin Struct Biol (2011) 1.35
Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem (2013) 1.26
Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology (2012) 1.18
The NuRD architecture. Cell Mol Life Sci (2013) 1.18
HDAC8 substrates: Histones and beyond. Biopolymers (2013) 1.08
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05
Investigating the selectivity of metalloenzyme inhibitors. J Med Chem (2013) 0.99
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS One (2012) 0.98
Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog (2013) 0.97
Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharm Pat Anal (2012) 0.94
Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother (2012) 0.94
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol (2013) 0.92
Small molecule inhibitors of zinc-dependent histone deacetylases. Neurotherapeutics (2013) 0.91
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Stimulation of histone deacetylase activity by metabolites of intermediary metabolism. J Biol Chem (2012) 0.91
Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol (2014) 0.90
Insight into the architecture of the NuRD complex: structure of the RbAp48-MTA1 subcomplex. J Biol Chem (2014) 0.89
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers. Chem Sci (2015) 0.85
idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach. Nucleic Acids Res (2012) 0.85
Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8. J Am Chem Soc (2013) 0.85
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett (2013) 0.84
The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. Bioorg Med Chem Lett (2012) 0.83
Computational exploration of zinc binding groups for HDAC inhibition. J Org Chem (2013) 0.81
STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis. JAKSTAT (2013) 0.80
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. J Med Chem (2014) 0.80
Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2. Bioorg Med Chem Lett (2012) 0.79
Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site. Inorg Chem (2013) 0.79
Computational design of a time-dependent histone deacetylase 2 selective inhibitor. ACS Chem Biol (2015) 0.79
A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy. ChemMedChem (2013) 0.78
In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease. Biomed Res Int (2014) 0.78
Potent Inducers of Endogenous Antimicrobial Peptides for Host Directed Therapy of Infections. Sci Rep (2016) 0.77
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query. Comb Chem High Throughput Screen (2015) 0.77
Synthesis of a new trifluoromethylketone analogue of l-arginine and contrasting inhibitory activity against human arginase I and histone deacetylase 8. Bioorg Med Chem Lett (2011) 0.77
A potential adjuvant chemotherapeutics, 18β-glycyrrhetinic acid, inhibits renal tubular epithelial cells apoptosis via enhancing BMP-7 epigenetically through targeting HDAC2. Sci Rep (2016) 0.77
Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells. Evid Based Complement Alternat Med (2015) 0.76
Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors. Adv Bioinformatics (2014) 0.76
Valproic acid as a potential inhibitor of Plasmodium falciparum histone deacetylase 1 (PfHDAC1): an in silico approach. Int J Mol Sci (2015) 0.75
A histone deacetylase-dependent screen in yeast. Bioorg Med Chem (2010) 0.75
Lysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulation. ChemMedChem (2014) 0.75
Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model. Int J Mol Sci (2013) 0.75
Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity. ACS Med Chem Lett (2017) 0.75
HDAC6 Brain Mapping with [(18)F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination. ACS Cent Sci (2017) 0.75
Chemical and structural biology of protein lysine deacetylases. Proc Jpn Acad Ser B Phys Biol Sci (2017) 0.75
Curcumin and hydroxamate-derivative (PCI-34058) interfere with histone deacetylase I catalytic core Asp-His charge relay system: atomistic simulation studies. J Mol Model (2015) 0.75
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 3.31
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem (2007) 1.73
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem (2011) 1.61
Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun (2006) 1.17
Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med (2014) 1.11
Quantitative analysis of anti-apoptotic function of Akt in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells under normal and stressed conditions. J Biol Chem (2006) 1.10
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J Med Chem (2010) 1.02
Conformational flexibility in crystal structures of human 11beta-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J Biol Chem (2004) 0.99
Identification of genes that are downregulated in the absence of the POU domain transcription factor pou3f1 (Oct-6, Tst-1, SCIP) in sciatic nerve. J Neurosci (2002) 0.95
Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. Anticancer Res (2004) 0.85
X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling. J Mol Biol (2010) 0.83
Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioorg Med Chem Lett (2006) 0.82
Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg Med Chem Lett (2004) 0.82
Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Bioorg Med Chem Lett (2013) 0.81
Design, synthesis and SAR of novel glucokinase activators. Bioorg Med Chem Lett (2013) 0.81
Corrigendum: The promise and peril of chemical probes. Nat Chem Biol (2015) 0.79
Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett (2006) 0.79
Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase inhibitors using liquid chromatography/tandem mass spectrometry detection. Rapid Commun Mass Spectrom (2006) 0.79
Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity. Bioorg Med Chem Lett (2010) 0.78
Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. Bioorg Med Chem Lett (2013) 0.78
A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT). J Med Chem (2014) 0.75
Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Bioorg Med Chem Lett (2002) 0.75
Use of high-throughput crystallography and in silico methods for structure-based drug design. Methods Biochem Anal (2005) 0.75